S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension
Sign Up to like & getrecommendations! Published in 2018 at "Thorax"
DOI: 10.1136/thorax-2018-212555.128
Abstract: Introduction Pulmonary arterial hypertension (PAH) is a progressive disease with a poor prognosis. In the event-driven GRIPHON study, selexipag significantly reduced the risk of a composite primary endpoint event of morbidity/mortality compared with placebo. Purpose… read more here.
Keywords: arterial hypertension; safety; griphon study; pulmonary arterial ... See more keywords